Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Altamira Therapeutics Ltd (CYTO)

NASDAQ
Currency in USD
Disclaimer
1.460
-0.040(-2.67%)
Real-time Data

CYTO Comments

bought at .65
  .87 here
Should keep it until tomorrow?
see what happens at end of the day I would say yeah.. ?
big money big money no whammys no whammys
big money big money no whammys no whammys
lets see $2 today....
You haven't done your homework, Tyler Hardig.
According to SEC, they have two phase 3 programs in progress. One in phase 1 and up for review October 17th, 2018.
All in with PURA!! eyes possibly that's why you see ppl buying the rumor selling the news been very popular of late. looks like up to $2 but will probably test .74-.85 before another leg up before news and I think news in no bueno just my thoughts haven't done much dd but they aren't far in any phase
They have two phase 3 programs in progress and one phase one program. The phase 3 programs are for inner hearing loss.
Plus they are or are about to be approved by the FDA
They were rated as a good RSI
No PR on company news. What’s the deal here?
what's the deal here? just a gap up or is this a company with coming news?
???
I noticed this also Raj..
what happened ? why going up?
Made 400k on todays profit
Let me have 10k
Teach me my Lord XD
Just need to pop through .95-.96 then the party begins. Pt 1.30
Get ready
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.